{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:50:34Z","timestamp":1791449434002,"version":"4.3.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13555-026-01911-x","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:27:19Z","timestamp":1790872039000},"page":"5215-5227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Ulrike","family":"Blume-Peytavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Craiglow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka Arun","family":"Netravali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Doche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Wajsbrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahmat","family":"Ishowo-Adejumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"2","key":"1911_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","volume":"14","author":"N Islam","year":"2015","unstructured":"Islam N, Leung PS, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.10.014.","journal-title":"Autoimmun Rev."},{"issue":"3","key":"1911_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","volume":"82","author":"HH Lee","year":"2020","unstructured":"Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675\u201382. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.032.","journal-title":"J Am Acad Dermatol"},{"key":"1911_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CCID.S245649","volume":"13","author":"M Benigno","year":"2020","unstructured":"Benigno M, Anastassopoulos KP, Mostaghimi A, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259\u201366. https:\/\/doi.org\/10.2147\/CCID.S245649.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"1911_CR4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1111\/jdv.14959","volume":"32","author":"MA Richard","year":"2018","unstructured":"Richard MA, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the \u00ab\u202fOBJECTIFS PEAU\u202f\u00bb study. J Eur Acad Dermatol Venereol. 2018;32(11):1967\u201371. https:\/\/doi.org\/10.1111\/jdv.14959.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"1911_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/bjd.20628","volume":"186","author":"M Harries","year":"2022","unstructured":"Harries M, Macbeth AE, Holmes S, et al. The epidemiology of alopecia areata: a population-based cohort study in UK primary care. Br J Dermatol. 2022;186(2):257\u201365. https:\/\/doi.org\/10.1111\/bjd.20628.","journal-title":"Br J Dermatol"},{"issue":"11","key":"1911_CR6","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1046\/j.1365-4362.2002.01357.x","volume":"41","author":"E Tan","year":"2002","unstructured":"Tan E, Tay YK, Goh CL, Chin Giam Y. The pattern and profile of alopecia areata in Singapore\u2014a study of 219 Asians. Int J Dermatol. 2002;41(11):748\u201353. https:\/\/doi.org\/10.1046\/j.1365-4362.2002.01357.x.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1911_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-4362.1992.tb03932.x","volume":"31","author":"WV Shellow","year":"1992","unstructured":"Shellow WV, Edwards JE, Koo JY. Profile of alopecia areata: a questionnaire analysis of patient and family. Int J Dermatol. 1992;31(3):186\u20139. https:\/\/doi.org\/10.1111\/j.1365-4362.1992.tb03932.x.","journal-title":"Int J Dermatol"},{"issue":"3","key":"1911_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000466704","volume":"3","author":"T Christensen","year":"2017","unstructured":"Christensen T, Yang JS, Castelo-Soccio L. Bullying and quality of life in pediatric alopecia areata. Skin Appendage Disord. 2017;3(3):115\u20138. https:\/\/doi.org\/10.1159\/000466704.","journal-title":"Skin Appendage Disord."},{"issue":"6","key":"1911_CR9","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaad.2021.04.077","volume":"86","author":"VR Barton","year":"2022","unstructured":"Barton VR, Toussi A, Awasthi S, Kiuru M. Treatment of pediatric alopecia areata: a systematic review. J Am Acad Dermatol. 2022;86(6):1318\u201334. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.077.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1911_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/s0190-9622(86)80482-0","volume":"14","author":"HO Beard","year":"1986","unstructured":"Beard HO. Social and psychological implications of alopecia areata. J Am Acad Dermatol. 1986;14(4):697\u2013700. https:\/\/doi.org\/10.1016\/s0190-9622(86)80482-0.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"1911_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/bjd\/ljae385","volume":"192","author":"MJ Harries","year":"2024","unstructured":"Harries MJ, Ascott A, Asfour L, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2024. Br J Dermatol. 2024;192(2):190\u2013205. https:\/\/doi.org\/10.1093\/bjd\/ljae385.","journal-title":"Br J Dermatol"},{"key":"1911_CR12","doi-asserted-by":"publisher","unstructured":"Ohyama M, Ito T, Amoh Y, et al. Japanese Dermatological Association\u2019s Clinical Practice Guidelines for alopecia areata: a complete English translated version. J Dermatol. 2025;52(10):e876\u2013e907. https:\/\/doi.org\/10.1111\/1346-8138.17859.","DOI":"10.1111\/1346-8138.17859"},{"issue":"4","key":"1911_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jdv.19768","volume":"38","author":"L Rudnicka","year":"2024","unstructured":"Rudnicka L, Arenbergerova M, Grimalt R, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687\u201394. https:\/\/doi.org\/10.1111\/jdv.19768.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1911_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.abd.2024.10.001","volume":"100","author":"PM Ramos","year":"2025","unstructured":"Ramos PM, Anzai A, Duque-Estrada B, et al. Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata. An Bras Dermatola. 2025;100(2):328\u201341. https:\/\/doi.org\/10.1016\/j.abd.2024.10.001.","journal-title":"An Bras Dermatola."},{"key":"1911_CR15","doi-asserted-by":"publisher","unstructured":"Lynde CW, Guenther L, Andriessen A, et al. A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics. Front Med. 2026;13:184624. https:\/\/doi.org\/10.3389\/fmed.2026.1846243.","DOI":"10.3389\/fmed.2026.1846243"},{"issue":"10387","key":"1911_CR16","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. Lancet. 2023;401(10387):1518\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(23)00222-2.","journal-title":"Lancet"},{"key":"1911_CR17","doi-asserted-by":"publisher","unstructured":"Hordinsky M, Hebert AA, Gooderham M, et al. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023;40(6):1003\u20139. https:\/\/doi.org\/10.1111\/pde.15378.","DOI":"10.1111\/pde.15378"},{"key":"1911_CR18","doi-asserted-by":"publisher","unstructured":"King B, Mirmirani P, Lo Sicco K, et al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025;39(6):1163\u201373. https:\/\/doi.org\/10.1111\/jdv.20547.","DOI":"10.1111\/jdv.20547"},{"issue":"6","key":"1911_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/bjd\/ljad253","volume":"189","author":"B King","year":"2023","unstructured":"King B, Shapiro J, Ohyama M, et al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023;189(6):666\u201373. https:\/\/doi.org\/10.1093\/bjd\/ljad253.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1911_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","volume":"25","author":"B King","year":"2024","unstructured":"King B, Soung J, Tziotzios C, et al. Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program. Am J Clin Dermatol. 2024;25(2):299\u2013314. https:\/\/doi.org\/10.1007\/s40257-024-00846-3.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"1911_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/bjd\/ljae365","volume":"192","author":"M Piliang","year":"2025","unstructured":"Piliang M, Soung J, King B, et al. Efficacy and safety of the oral Janus kinase 3\/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb\/III and long-term phase III clinical studies in alopecia areata. Br J Dermatol. 2025;192(2):215\u201327. https:\/\/doi.org\/10.1093\/bjd\/ljae365.","journal-title":"Br J Dermatol"},{"key":"1911_CR22","doi-asserted-by":"publisher","unstructured":"Tziotzios C, Sinclair R, Lesiak A, et al. Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: results from the ALLEGRO-LT phase 3, open-label study. J Eur Acad Dermatol Venereol. 2025;39(6):1152\u201362. https:\/\/doi.org\/10.1111\/jdv.20526.","DOI":"10.1111\/jdv.20526"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01911-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:00:31Z","timestamp":1791446431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01911-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1911"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01911-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ulrike Blume-Peytavi has received honoraria for lectures, advisory board, and\/or clinical studies from AbbVie, Amryt, Bayer, Boots Healthcare, Cantabria Labs, Cassiopeia, CeraVe, Concert Pharmaceuticals\/Sun Pharma, Dermocosm\u00e9tique Vichy, Galderma Laboratorium GmbH, Eli Lilly, Laboratoires Bailleuil, Legacy Healthcare, LEO-Pharma, Novartis, Pfizer, Sanofi, and Regeneron. Brittany Craiglow has received honoraria and\/or fees from AbbVie, BiologicsMD, Dermavant, Eli Lilly, Incyte, Pfizer, Regeneron, Sanofi-Genzyme, and Sun Pharmaceuticals. Ilka Arun Netravali is involved in performing clinical trials and\/or is a member of commercial and scientific advisory boards, consultant, and\/or speaker for Arcutis Biotherapeutics, Inc., Eli Lilly and Company, Pfizer Inc, and Verrica Pharmaceuticals Inc. Isabella Doche has received honoraria and\/or fees from Pfizer, Pierre Fabre-Ducray, Loreal, Theraskin, Ache, GSK, Cantabria Lab, and Panalab, and royalties from Jaypee Medical Publisher. Kazutoshi Harada has received lecture fees and\/or advisory fees from Eli Lilly, Janssen Pharmaceuticals, Maruho, and Pfizer Inc, and research funding for clinical trials from Eli Lilly. Gianluca Bonfanti is an employee of Engineering Ingegneria Informatica, which is a paid subcontractor to Health Services Consulting Corporation. Dalia Wajsbrot, Rahmat Ishowo-Adejumo, Robert Wolk, and Helen Tran are employees of Pfizer Inc. and hold stock or stock options in Pfizer Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the protocol and with the consensus ethical principles derived from international guidelines, including the Declaration of Helsinki and CIOMS International Ethical Guidelines; applicable International Council for Harmonisation Good Clinical Practice guidelines; and applicable regional laws and regulations, including privacy laws. All participants or their legally authorized representative provided written informed consent. The protocols for the studies on which this analysis was based were reviewed and approved by the institutional review boards or ethics committees of the participating institutions.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}